FDA Requests Suicidality Event Review For Epilepsy Drugs
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA is requesting that 14 manufacturers of anti-epileptic drugs re-examine clinical trial data to identify potential suicide-related adverse events. The analyses will be modeled on the agency’s recent re-examination of antidepressant data. FDA’s request to epilepsy drug sponsors follows suicidality signals seen in some trials.
You may also be interested in...
FDA Requests Adult Antidepressant Suicidality Data
The agency's review of adult suicidality data will take at least a year to complete, FDA says in a Public Health Advisory. Manufacturers of antidepressants are being asked to review all placebo-controlled trials in adult patients using methodology similar to that used to analyze suicidality in pediatric trials.
FDA Requests Adult Antidepressant Suicidality Data
The agency's review of adult suicidality data will take at least a year to complete, FDA says in a Public Health Advisory. Manufacturers of antidepressants are being asked to review all placebo-controlled trials in adult patients using methodology similar to that used to analyze suicidality in pediatric trials.
FDA Analysis Of Antidepressant Pediatric Suicidality Data To Be Reviewed Sept. 13-14
Joint meeting of Psychopharmacologic and newly formed Pediatric Advisory Committees will review analysis performed by expert group assembled by Columbia University. Future research needs in pediatric suicidality will also be addressed.